Cargando…
Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma
BACKGROUND: LipoxinA4 (LXA4) is an anti-inflammatory lipid mediator which was recently proposed to have antitumor potential. However, the therapeutic effect of LXA4 in melanoma is still unclear. This work aimed to investigate the function of LXA4 and its analog in melanoma invasion through in vivo a...
Autores principales: | Du, Yu, Yang, Jianing, Su, Tangfeng, Shen, Zhu, Li, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246158/ https://www.ncbi.nlm.nih.gov/pubmed/34268415 http://dx.doi.org/10.21037/atm-21-1873 |
Ejemplares similares
-
Erratum to lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma
Publicado: (2022) -
The Lipoxin Receptor/FPR2 Agonist BML-111 Protects Mouse Skin against Ultraviolet B Radiation
por: Martinez, Renata M., et al.
Publicado: (2020) -
The Lipoxin A4 Receptor Agonist BML-111 Alleviates Inflammatory Injury and Oxidative Stress in Spinal Cord Injury
por: Liu, Jian, et al.
Publicado: (2020) -
Effect of the Lipoxin Receptor Agonist BML-111 on Cigarette Smoke Extract-Induced Macrophage Polarization and Inflammation in RAW264.7 Cells
por: Cao, En, et al.
Publicado: (2023) -
Lipoxin A4 receptor agonist BML-111 induces autophagy in alveolar macrophages and protects from acute lung injury by activating MAPK signaling
por: Liu, Huaizheng, et al.
Publicado: (2018)